{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:18:41Z","timestamp":1759364321224,"version":"build-2065373602"},"reference-count":59,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychiatric Clinics of North America"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.psc.2022.04.001","type":"journal-article","created":{"date-parts":[[2022,7,31]],"date-time":"2022-07-31T07:02:07Z","timestamp":1659250927000},"page":"335-346","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Pharmacotherapy of Opioid Use Disorder\u2014Update and Current Challenges"],"prefix":"10.1016","volume":"45","author":[{"given":"Savitha","family":"Racha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan","family":"Buresh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Fingerhood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2019","series-title":"Engineering, and medicine; Health and medicine Division; board on Health Sciences Policy; Committee on medication-Assisted treatment for opioid Use disorder","key":"10.1016\/j.psc.2022.04.001_bib1"},{"year":"2020","series-title":"The American Society of addiction medicine Handbook of addiction medicine","author":"Rastegar","key":"10.1016\/j.psc.2022.04.001_bib2"},{"issue":"5","key":"10.1016\/j.psc.2022.04.001_bib3","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1176\/appi.ps.201600056","article-title":"Social Stigma Toward Persons With Prescription Opioid Use Disorder: Associations With Public Support for Punitive and Public Health-Oriented Policies","volume":"68","author":"Kennedy-Hendricks","year":"2017","journal-title":"Psychiatr Serv"},{"key":"10.1016\/j.psc.2022.04.001_bib4","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.drugalcdep.2016.05.010","article-title":"Primary care physicians' perspectives on the prescription opioid epidemic","volume":"165","author":"Kennedy-Hendricks","year":"2016","journal-title":"Drug Alcohol Depend"},{"year":"2019","series-title":"Key substance Use and Mental Health Indicators in the United States: results from the 2018 national survey on drug Use and Health","author":"Substance Abuse and Mental Health Services Administration","key":"10.1016\/j.psc.2022.04.001_bib5"},{"issue":"15","key":"10.1016\/j.psc.2022.04.001_bib6","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1001\/jama.2016.1464","article-title":"CDC Guideline for Prescribing Opioids for Chronic Pain--United States, 2016","volume":"315","author":"Dowell","year":"2016","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.psc.2022.04.001_bib7","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.pain.2004.09.019","article-title":"Opioids in chronic non-cancer pain: systematic review of efficacy and safety","volume":"112","author":"Kalso","year":"2004","journal-title":"Pain"},{"issue":"1","key":"10.1016\/j.psc.2022.04.001_bib8","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1186\/s12913-019-4751-4","article-title":"Opioid use disorder and treatment: challenges and opportunities","volume":"19","author":"Hoffman","year":"2019","journal-title":"BMC Health Serv Res"},{"issue":"2","key":"10.1016\/j.psc.2022.04.001_bib9","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1503\/cmaj.122099","article-title":"Don't tamper with oxycodone","volume":"185","author":"Fletcher","year":"2013","journal-title":"CMAJ"},{"issue":"50","key":"10.1016\/j.psc.2022.04.001_bib10","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.15585\/mmwr.mm7050e3","article-title":"Trends in and Characteristics of Drug Overdose Deaths Involving Illicitly Manufactured Fentanyls - United States, 2019-2020","volume":"70","author":"O'Donnell","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"10.1016\/j.psc.2022.04.001_bib11","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/s41398-019-0625-0","article-title":"The rising crisis of illicit fentanyl use, overdose, and potential therapeutic strategies","volume":"9","author":"Han","year":"2019","journal-title":"Transl Psychiatry"},{"issue":"8","key":"10.1016\/j.psc.2022.04.001_bib12","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1001\/jama.1991.03460080081037","article-title":"An outbreak of designer drug--related deaths in Pennsylvania","volume":"265","author":"Hibbs","year":"1991","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.psc.2022.04.001_bib13","doi-asserted-by":"crossref","first-page":"439","DOI":"10.3109\/15563659509013752","article-title":"Fentanyl: a review for clinical and analytical toxicologists","volume":"33","author":"Poklis","year":"1995","journal-title":"J\u00a0Toxicol Clin Toxicol"},{"issue":"17","key":"10.1016\/j.psc.2022.04.001_bib14","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1001\/jama.2018.2844","article-title":"Changes in Synthetic Opioid Involvement in Drug Overdose Deaths in the United States, 2010-2016","volume":"319","author":"Jones","year":"2018","journal-title":"JAMA"},{"issue":"6408","key":"10.1016\/j.psc.2022.04.001_bib15","doi-asserted-by":"crossref","DOI":"10.1126\/science.aau1184","article-title":"Changing dynamics of the drug overdose epidemic in the United States from 1979 through 2016","volume":"361","author":"Jalal","year":"2018","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.psc.2022.04.001_bib16","first-page":"404","article-title":"The Opioid Crisis in Black Communities","volume":"46","author":"James","year":"2018","journal-title":"J\u00a0L Med Ethics"},{"key":"10.1016\/j.psc.2022.04.001_bib17","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/j.1749-6632.2000.tb06683.x","article-title":"Methadone-related opioid agonist pharmacotherapy for heroin addiction. History, recent molecular and neurochemical research and future in mainstream medicine","volume":"909","author":"Kreek","year":"2000","journal-title":"Ann N Y Acad Sci"},{"issue":"22","key":"10.1016\/j.psc.2022.04.001_bib18","first-page":"1936","article-title":"Effective medical treatment of opiate addiction. National Consensus Development Panel on Effective Medical Treatment of Opiate Addiction","volume":"280","year":"1998","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.psc.2022.04.001_bib20","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1056\/NEJMra1604339","article-title":"Treatment of Opioid-Use Disorders","volume":"375","author":"Schuckit","year":"2016","journal-title":"N\u00a0Engl J Med"},{"article-title":"Methadone","year":"2022","author":"Durrani","key":"10.1016\/j.psc.2022.04.001_bib21"},{"issue":"1\u20132","key":"10.1016\/j.psc.2022.04.001_bib22","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.drugalcdep.2009.05.021","article-title":"Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: risk factors and lives saved","volume":"105","author":"Degenhardt","year":"2009","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"10.1016\/j.psc.2022.04.001_bib23","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/s13181-018-0685-1","article-title":"Pharmacologic Treatment of Opioid Use Disorder: a Review of Pharmacotherapy, Adjuncts, and Toxicity","volume":"14","author":"Toce","year":"2018","journal-title":"J\u00a0Med Toxicol"},{"issue":"4","key":"10.1016\/j.psc.2022.04.001_bib24","doi-asserted-by":"crossref","first-page":"455","DOI":"10.31887\/DCNS.2007.9.2\/hkleber","article-title":"Pharmacologic treatments for opioid dependence: detoxification and maintenance options","volume":"9","author":"Kleber","year":"2007","journal-title":"Dialogues Clin Neurosci"},{"issue":"5","key":"10.1016\/j.psc.2022.04.001_bib25","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1093\/bja\/ael051","article-title":"Buprenorphine induces ceiling in respiratory depression but not in analgesia","volume":"96","author":"Dahan","year":"2006","journal-title":"Br J Anaesth"},{"issue":"7","key":"10.1016\/j.psc.2022.04.001_bib26","doi-asserted-by":"crossref","first-page":"e2117128","DOI":"10.1001\/jamanetworkopen.2021.17128","article-title":"High-Dose Buprenorphine Induction in the Emergency Department for Treatment of Opioid Use Disorder","volume":"4","author":"Herring","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.psc.2022.04.001_bib27","first-page":"122","article-title":"Micro-dosing Intravenous Buprenorphine to Rapidly Transition From Full Opioid Agonists","volume":"16","author":"Thakrar","year":"2022","journal-title":"J\u00a0Addict Med"},{"issue":"5","key":"10.1016\/j.psc.2022.04.001_bib28","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/dar.13113","article-title":"Use of a novel prescribing approach for the treatment of opioid use disorder: Buprenorphine\/naloxone micro-dosing - a case series","volume":"39","author":"Brar","year":"2020","journal-title":"Drug Alcohol Rev"},{"key":"10.1016\/j.psc.2022.04.001_bib29","first-page":"1","article-title":"Transdermal buprenorphine for in-hospital transition from full agonist opioids to sublingual buprenorphine: a retrospective observational cohort study [published online ahead of print, 2022 Jan 20]","author":"Baumgartner","year":"2022","journal-title":"Clin Toxicol (Phila)"},{"issue":"2","key":"10.1016\/j.psc.2022.04.001_bib30","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/HRP.0000000000000075","article-title":"Medication-assisted treatment of opioid use disorder: review of the evidence and future directions","volume":"23","author":"Connery","year":"2015","journal-title":"Harv Rev Psychiatry"},{"issue":"2","key":"10.1016\/j.psc.2022.04.001_bib31","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/dar.13017","article-title":"High-dose buprenorphine for treatment of high potency opioid use disorder","volume":"39","author":"Danilewitz","year":"2020","journal-title":"Drug Alcohol Rev"},{"issue":"10173","key":"10.1016\/j.psc.2022.04.001_bib32","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/S0140-6736(18)32259-1","article-title":"Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"393","author":"Haight","year":"2019","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.psc.2022.04.001_bib33","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1001\/jamainternmed.2018.1052","article-title":"Weekly and Monthly Subcutaneous Buprenorphine Depot Formulations vs Daily Sublingual Buprenorphine With Naloxone for Treatment of Opioid Use Disorder: A Randomized Clinical Trial","volume":"178","author":"Lofwall","year":"2018","journal-title":"JAMA Intern Med"},{"issue":"4","key":"10.1016\/j.psc.2022.04.001_bib34","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1056\/NEJMoa055255","article-title":"Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence","volume":"355","author":"Fiellin","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.psc.2022.04.001_bib35","article-title":"Get waivered remote: Nationwide, remote DEA-x waiver course in response to COVID-19","volume":"7","author":"Martin","year":"2021","journal-title":"Digit Health"},{"issue":"3","key":"10.1016\/j.psc.2022.04.001_bib36","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1080\/00952990.2018.1545131","article-title":"A\u00a0retrospective cohort study of mortality rates in patients with an opioid use disorder treated with implant naltrexone, oral methadone or sublingual buprenorphine","volume":"45","author":"Kelty","year":"2019","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"5","key":"10.1016\/j.psc.2022.04.001_bib37","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1176\/appi.ajp.2016.16050548","article-title":"Long-Acting Injectable Naltrexone Induction: A Randomized Trial of Outpatient Opioid Detoxification With Naltrexone Versus Buprenorphine","volume":"174","author":"Sullivan","year":"2017","journal-title":"Am J Psychiatry"},{"issue":"1","key":"10.1016\/j.psc.2022.04.001_bib38","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12954-018-0271-5","article-title":"Rigidity, dyskinesia and other atypical overdose presentations observed at a supervised injection site, Vancouver, Canada","volume":"15","author":"Kinshella","year":"2018","journal-title":"Harm Reduct J"},{"issue":"6","key":"10.1016\/j.psc.2022.04.001_bib39","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1080\/15563650701877374","article-title":"Fentanyl epidemic in Chicago, Illinois and surrounding Cook County","volume":"46","author":"Schumann","year":"2008","journal-title":"Clin Toxicol (Phila)"},{"key":"10.1016\/j.psc.2022.04.001_bib40","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.drugalcdep.2018.07.019","article-title":"Methadone maintenance treatment among patients exposed to illicit fentanyl in Rhode Island: Safety, dose, retention, and relapse at 6\u00a0months","volume":"192","author":"Stone","year":"2018","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"10.1016\/j.psc.2022.04.001_bib41","first-page":"253","article-title":"Impact of Fentanyl Use on Buprenorphine Treatment Retention and Opioid Abstinence","volume":"13","author":"Wakeman","year":"2019","journal-title":"J\u00a0Addict Med"},{"issue":"10118","key":"10.1016\/j.psc.2022.04.001_bib42","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(17)32812-X","article-title":"Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial","volume":"391","author":"Lee","year":"2018","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.psc.2022.04.001_bib43","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1080\/14740338.2019.1613372","article-title":"The role of take-home naloxone in the epidemic of opioid overdose involving illicitly manufactured fentanyl and its analogs","volume":"18","author":"Kim","year":"2019","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.psc.2022.04.001_bib44","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ejphar.2014.05.044","article-title":"Nalmefene reverses carfentanil-induced loss of righting reflex and respiratory depression in rats","volume":"738","author":"Yong","year":"2014","journal-title":"Eur J Pharmacol"},{"issue":"6","key":"10.1016\/j.psc.2022.04.001_bib45","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1111\/jphp.13079","article-title":"Prolonged therapy with the anticonvulsant carbamazepine leads to increased plasma clearance of fentanyl","volume":"71","author":"Nozari","year":"2019","journal-title":"J\u00a0Pharm Pharmacol"},{"issue":"2","key":"10.1016\/j.psc.2022.04.001_bib46","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1124\/jpet.118.253674","article-title":"A\u00a0Fentanyl Vaccine Alters Fentanyl Distribution and Protects against Fentanyl-Induced Effects in Mice and Rats","volume":"368","author":"Raleigh","year":"2019","journal-title":"J\u00a0Pharmacol Exp Ther"},{"issue":"26","key":"10.1016\/j.psc.2022.04.001_bib47","doi-asserted-by":"crossref","first-page":"10489","DOI":"10.1021\/jacs.9b04872","article-title":"Monoclonal Antibodies for Combating Synthetic Opioid Intoxication","volume":"141","author":"Smith","year":"2019","journal-title":"J\u00a0Am Chem Soc"},{"issue":"3","key":"10.1016\/j.psc.2022.04.001_bib48","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1080\/00952990.2019.1694536","article-title":"A\u00a0systematic review of rural-specific barriers to medication treatment for opioid use disorder in the United States","volume":"46","author":"Lister","year":"2020","journal-title":"Am J Drug Alcohol Abuse"},{"key":"10.1016\/j.psc.2022.04.001_bib49","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2020.557275","article-title":"Patient Satisfaction With Medications for Opioid Use Disorder Treatment via Telemedicine: Brief Literature Review and Development of a New Assessment","volume":"8","author":"Cole","year":"2021","journal-title":"Front Public Health"},{"issue":"5","key":"10.1016\/j.psc.2022.04.001_bib50","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1111\/j.1360-0443.2011.03700.x","article-title":"Randomized trial of standard methadone treatment compared to initiating methadone without counseling: 12-month findings","volume":"107","author":"Schwartz","year":"2012","journal-title":"Addiction"},{"key":"10.1016\/j.psc.2022.04.001_bib52","doi-asserted-by":"crossref","first-page":"108149","DOI":"10.1016\/j.jsat.2020.108149","article-title":"Mobile van delivery of extended-release buprenorphine and extended-release naltrexone for youth with OUD: An adaptation to the COVID-19 emergency","volume":"120","author":"Wenzel","year":"2021","journal-title":"J\u00a0Subst Abuse Treat"},{"key":"10.1016\/j.psc.2022.04.001_bib53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jsat.2019.05.002","article-title":"Expanding low-threshold buprenorphine to justice-involved individuals through mobile treatment: Addressing a critical care gap","volume":"103","author":"Krawczyk","year":"2019","journal-title":"J\u00a0Subst Abuse Treat"},{"issue":"4","key":"10.1016\/j.psc.2022.04.001_bib54","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1001\/jamapsychiatry.2017.4614","article-title":"Postincarceration Fatal Overdoses After Implementing Medications for Addiction Treatment in a Statewide Correctional System","volume":"75","author":"Green","year":"2018","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.psc.2022.04.001_bib56","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12954-015-0088-4","article-title":"Why the FUSS (Fentanyl Urine Screen Study)? A cross-sectional survey to characterize an emerging threat to people who use drugs in British Columbia, Canada","volume":"12","author":"Amlani","year":"2015","journal-title":"Harm Reduct J"},{"issue":"1_suppl","key":"10.1016\/j.psc.2022.04.001_bib57","doi-asserted-by":"crossref","first-page":"80S","DOI":"10.1177\/00333549211042829","article-title":"Improvements in Toxicology Testing to Identify Fentanyl Analogs and Other Novel Synthetic Opioids in Fatal Drug Overdoses, Connecticut, January 2016-June 2019","volume":"136","author":"Clinton","year":"2021","journal-title":"Public Health Rep"},{"issue":"1","key":"10.1016\/j.psc.2022.04.001_bib58","first-page":"33","article-title":"Urine Drug Tests: Ordering and Interpreting Results","volume":"99","author":"Kale","year":"2019","journal-title":"Am Fam Physician"},{"issue":"Pt A","key":"10.1016\/j.psc.2022.04.001_bib59","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.neuropharm.2017.10.016","article-title":"Fentanyl, fentanyl analogs and novel synthetic opioids: A comprehensive review","volume":"134","author":"Armenian","year":"2018","journal-title":"Neuropharmacology"},{"year":"2019","series-title":"The Asam Principles of addiction medicine","author":"Miller","key":"10.1016\/j.psc.2022.04.001_bib60"},{"issue":"9","key":"10.1016\/j.psc.2022.04.001_bib61","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1001\/jamapsychiatry.2021.0976","article-title":"Association of Opioid Agonist Treatment With All-Cause Mortality and Specific Causes of Death Among People With Opioid Dependence: A Systematic Review and Meta-analysis [published correction appears in JAMA Psychiatry. 2021 Sep 1;78(9):1044]","volume":"78","author":"Santo","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.psc.2022.04.001_bib62","first-page":"CD002207","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","volume":"3","author":"Mattick","year":"2004","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Psychiatric Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0193953X22000260?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0193953X22000260?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T01:42:04Z","timestamp":1759282924000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0193953X22000260"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":59,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S0193953X22000260"],"URL":"https:\/\/doi.org\/10.1016\/j.psc.2022.04.001","relation":{},"ISSN":["0193-953X"],"issn-type":[{"type":"print","value":"0193-953X"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacotherapy of Opioid Use Disorder\u2014Update and Current Challenges","name":"articletitle","label":"Article Title"},{"value":"Psychiatric Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psc.2022.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}